A Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFDA Accepts New Drug Application for 3-Month Formulation of Leuprolide Mesylate for Advanced Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 2: Iodine-131 PSMA Radioligand with Enzalutamide Shows Promise in ARROW trial for metastatic castration-resistant prostate cancer (mCRPC)
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPost-hoc of ARASENS for metastatic hormone sensitive prostate cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxDarolutamide Plus ADT and Docetaxel Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in ARASENS Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025
- Phase 1 Trial For BL-M14D1 For Neuroendocrine Cancers July 28, 2025